Inhibrx Biosciences, Inc. · NASDAQ:INBX

Inhibrx Biosciences — BSG Annual Meeting 2026

17 slides from Inhibrx Biosciences's conference presentation, February 2026

  1. Slide 1: Ozekibart (INBRX-109) in Conventional Chondrosarcoma: ChonDRAgon Phase 2 Results

    Session 7 The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study Robin L. Jones,1 Victoria Wang,2 Mark Doherty,3 Ana Sebio García,4 Silvia Stacchiotti,5 Breelyn A. Wilky,6 Jean-Yves Blay,7 P

  2. Slide 2: Presenter Disclosures

    Presenter Disclosures R.L. Jones reports receipt of grants/research support from MSD and GSK, and has received consultancy fees from Adaptimmune, Adcendo, Advenchen, Agenus, Astex, Athenex, Avacta, Ayala, Bayer, Boehringer Ingelheim, Blueprint, Cogent, Clinigen, Eisai, Epizyme, Daichii Sankyo, Decip

  3. Slide 3: Presentation Disclaimer

    Presentation Disclaimer This presentation of Inhibrx Biosciences, Inc. (the “Company”) contains forward-looking Actual results or events could differ materially from the plans, intentions and expectations statements. In some cases, you can identify forward-looking statements by the words disclosed i

  4. Slide 4: Background

    Background  Unresectable or metastatic chondrosarcoma is associated with Structure of Ozekibart poor outcomes (mPFS of 2-4 months)1; systemic treatment options are limited  Ozekibart (INBRX-109) is a next-generation, recombinant, humanized, DR5: sdAb DR5: sdAb tetravalent DR5 agonist2 – DR5 is a m

  5. Slide 5: ChonDRAgon Study Design

    ChonDRAgon Study Design Blinded Open label Off Patients treatment Ozekibart • Age 18 to 85 years 3 mg/kg IV Q3W • Metastatic or unresectable conventional CS n=137 Blinded • Radiographic progression per RECIST 1.1 R treatment within 6 months of study treatment initiation 2:1 until PD Placebo • BMI <3

  6. Slide 6: Baseline Characteristics

    Baseline Characteristics Ozekibart Placebo Patient characteristic (n=137) (n=69) Age, median (range), years 54.0 (20-82) 50.0 (19-91) Sex, n (%) Male 96 (70.1) 42 (60.9) Female 41 (29.9) 27 (39.1) Race, n (%) White 114 (83.2) 47 (68.1) Othera 23 (16.8) 22 (31.9) Histological grade, n (%) 2 96 (70.1)

  7. Slide 7: Patient Disposition

    Patient Disposition Ozekibart Placebo Patient characteristic (n=137) (n=69) ITT 137 (100) 69 (100) Patients treated 136 (99.3) 67 (97.1) Ongoing treatment 25 (18.2) 3 (4.3) Discontinued treatment 112 (81.8) 66 (95.7) Crossed over to receive ozekibart N/A 44 (63.8) Reasons for discontinuation Disease

  8. Slide 8: Primary Endpoint: Progression-Free Survival by CIRR

    Primary Endpoint: Progression-Free Survival by CIRR 1.0 Ozekibart Placebo n=137 n=69 Events/censored, n (%) 94 (68.6)/43 (31.4) 55 (79.7)/14 (20.3) 0.8 mPFS, months 5.52 2.66 Probability of PFS Stratified HR (95.02% CI) 0.479 (0.335-0.684) 0.6 Log-rank P value <0.0001 0.4 0.2 Ozekibart Placebo 0.0 0

  9. Slide 9: Primary Endpoint: Progression-Free Survival by CIRR

    Primary Endpoint: Progression-Free Survival by CIRR 3 months 6 months 12 months 1.0 Ozekibart Placebo n=137 n=69 70.1% Events/censored, n (%) 94 (68.6)/43 (31.4) 55 (79.7)/14 (20.3) 0.8 mPFS, months 5.52 2.66 Probability of PFS 47.2% Stratified HR (95.02% CI) 0.479 (0.335-0.684) 0.6 Log-rank P value

  10. Slide 10: Progression-Free Survival by CIRR: Subgroup Analyses

    Progression-Free Survival by CIRR: Subgroup Analyses Favors ozekibart Ozekibart Placebo Events, mPFS, Events, mPFS, HR (95% CI) n/Na mo n/Na mo IDH mutation Wild type 65/93 5.5 38/47 2.7 0.493 (0.324-0.750) status Mutant 29/44 5.5 17/22 2.3 0.442 (0.224-0.871) Yes 38/58 5.3 21/28 2.7 0.546 (0.307-0.

  11. Slide 11: Progression-Free Survival by CIRR: Subgroup Analyses

    Progression-Free Survival by CIRR: Subgroup Analyses Favors ozekibart Ozekibart Placebo Events, mPFS, Events, mPFS, HR (95% CI) n/Na mo n/Na mo IDH mutation Wild type 65/93 5.5 38/47 2.7 0.493 (0.324-0.750) status Mutant 29/44 5.5 17/22 2.3 0.442 (0.224-0.871) Yes 38/58 5.3 21/28 2.7 0.546 (0.307-0.

  12. Slide 12: Overall Safety

    Overall Safety Ozekibart Placebo (n=136) (n=67) Patients with ≥1 AE (including unrelated AEs), n (%) 129 (94.9) 62 (92.5) Grade ≥3 53 (39.0) 17 (25.4) SAE 38 (27.9) 12 (17.9) HAE 21 (15.4) 9 (13.4) Resulting in death 5 (3.7) 1 (1.5) Patients with ≥1 treatment-related AE, n (%) 77 (56.6) 32 (47.8) Gr

  13. Slide 13: Most Common Adverse Events

    Most Common Adverse Events, including unrelated AEs (in ≥10% of Patients in Either Arm) Fatigue 22.8 26.9 Constipation 18.4 0.7 14.9 Diarrhea 14.7 0.7 4.5 Dyspnea 13.2 3.7 3.0 13.4 Anemia 13.2 2.9 11.9 Cough 13.2 16.4 Nausea 13.2 0.7 17.9 Back pain 12.5 2.2 4.5 9.0 Ozekibart (n=136) Pain in extremit

  14. Slide 14: Most Common Treatment-Related Adverse Events

    Most Common Treatment-Related Adverse Events (in ≥5% of Patients in Either Arm)  The most common treatment-related adverse events with ozekibart were fatigue, diarrhea, and nausea Fatigue 13.2 17.9 – Most treatment-related adverse events were grade 1 or 2 Diarrhea 8.8 4.5  The incidence of treatme

  15. Slide 15: Conclusions

    Conclusions  Unprecedented data in chondrosarcoma: ChonDRAgon is the largest randomized trial in chondrosarcoma and demonstrated that ozekibart significantly reduced risk of disease progression or death by 52% compared with placebo (HR, 0.479; 95.02% CI, 0.335–0.684)  Robust and significant PFS im

  16. Slide 16: Acknowledgments

    Acknowledgments Scan here to download the  We thank our patients and participating clinical sites and teams presentation  This study is sponsored by Inhibrx Biosciences, Inc.  Medical editorial assistance with this presentation was provided by Jenna M. Gaska, PhD, of Nucleus Global, an Inizio com

  17. Slide 17: Thank you!

    Thank you! Scan here to download the presentation

Inhibrx Biosciences — BSG Annual Meeting 2026 on 6ix